NADAC acquisition cost data for HUMULIN 70/30 KWIKPEN. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00002880359 | $30.23 | 2022-02-23 | OTC |
| 00002880359 | $30.23 | 2022-02-23 | OTC |
| 00002880359 | $30.23 | 2022-02-23 | OTC |
| 00002880359 | $30.23 | 2022-02-23 | OTC |
| 00002880359 | $30.23 | 2022-02-23 | OTC |
| 00002880359 | $30.23 | 2022-02-23 | OTC |
| 00002880359 | $30.23 | 2022-02-23 | OTC |
| 00002880359 | $30.23 | 2022-02-23 | OTC |
| 00002880359 | $30.23 | 2022-02-23 | OTC |
| 00002880359 | $30.23 | 2022-02-23 | OTC |
Generic: Insulin NPh Hum/Reg Insulin Hm | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $158.7M | 388,578 | 75,518 | $13.20 |
| 2020 | $152.2M | 364,301 | 69,046 | $13.12 |
| 2021 | $141.8M | 328,356 | 63,987 | $13.13 |
| 2022 | $128.6M | 293,478 | 57,827 | $13.12 |
| 2023 | $117.0M | 261,964 | 53,022 | $13.09 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| Puerto Rico | $30.7M | 85,520 | 12,367 |
| California | $12.7M | 34,331 | 9,181 |
| Texas | $10.5M | 18,175 | 4,578 |
| Florida | $7.4M | 14,467 | 3,456 |
| Georgia | $3.7M | 9,035 | 2,111 |
| Alabama | $3.6M | 6,894 | 1,437 |
| Illinois | $3.3M | 6,392 | 1,436 |
| Virginia | $3.1M | 6,162 | 1,478 |
| Ohio | $2.8M | 4,885 | 1,105 |
| North Carolina | $2.7M | 5,320 | 1,175 |
| Arizona | $2.6M | 4,276 | 1,052 |
| Tennessee | $2.3M | 4,300 | 970 |
| Pennsylvania | $2.2M | 4,684 | 1,039 |
| Indiana | $2.0M | 3,119 | 699 |
| Michigan | $1.9M | 3,465 | 879 |
| Washington | $1.9M | 3,449 | 879 |
| Wisconsin | $1.7M | 2,718 | 578 |
| New York | $1.7M | 3,589 | 895 |
| Kentucky | $1.7M | 2,842 | 577 |
| Missouri | $1.5M | 2,526 | 538 |
| South Carolina | $1.4M | 2,782 | 625 |
| Arkansas | $1.3M | 2,492 | 511 |
| New Jersey | $1.3M | 3,114 | 656 |
| Oregon | $1.1M | 2,329 | 663 |
| Massachusetts | $1.0M | 1,998 | 469 |
| Maryland | $982.0K | 3,515 | 955 |
| Nevada | $916.9K | 1,428 | 377 |
| Louisiana | $886.3K | 2,059 | 455 |
| Mississippi | $873.7K | 1,775 | 422 |
| Colorado | $819.1K | 1,818 | 501 |
| Oklahoma | $756.6K | 1,217 | 267 |
| Minnesota | $630.6K | 1,114 | 273 |
| Rhode Island | $583.8K | 1,015 | 211 |
| Utah | $470.0K | 726 | 181 |
| Connecticut | $458.8K | 953 | 211 |
| Iowa | $402.8K | 821 | 168 |
| New Mexico | $362.9K | 686 | 177 |
| Kansas | $343.2K | 741 | 141 |
| New Hampshire | $338.0K | 574 | 129 |
| Idaho | $308.6K | 524 | 124 |
| West Virginia | $269.1K | 398 | 98 |
| Nebraska | $250.6K | 510 | 90 |
| Maine | $219.1K | 320 | 85 |
| District of Columbia | $195.1K | 609 | 186 |
| Hawaii | $167.6K | 527 | 144 |
| Virgin Islands | $164.6K | 442 | 82 |
| Delaware | $110.8K | 202 | 53 |
| Montana | $84.6K | 178 | 31 |
| Guam | $70.2K | 244 | 43 |
| Vermont | $66.7K | 132 | 26 |
| South Dakota | $57.4K | 124 | 31 |
| Wyoming | $56.5K | 96 | 24 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.